Altrinsic Global Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Altrinsic Global Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-270,000	Closed	-$1.9M	–	77
2021 Q4	$1.9M	Hold	270,000	–	–	0.06%	58
2021 Q3	$3.08M	Buy	270,000 +30,000	+13%	+$439K	0.09%	54
2021 Q2	$3.84M	Hold	240,000	–	–	0.12%	52
2021 Q1	$4.29M	Hold	240,000	–	–	0.14%	53
2020 Q4	$3.24M	Buy	240,000 +30,000	+14%	+$363K	0.11%	50
2020 Q3	$2.47M	Buy	210,000 +60,000	+40%	+$731K	0.1%	52
2020 Q2	$2.21M	Buy	150,000 +30,000	+25%	+$444K	0.1%	53
2020 Q1	$1.62M	Hold	120,000	–	–	0.09%	54
2019 Q4	$2.9M	Hold	120,000	–	–	0.12%	47
2019 Q3	$2.31M	Buy	120,000 +10,000	+9%	+$229K	0.1%	51
2019 Q2	$3.25M	Buy	110,000 +15,000	+16%	+$578K	0.15%	47
2019 Q1	$4.51M	Hold	95,000	–	–	0.21%	45
2018 Q4	$3.43M	Buy	95,000 +65,000	+217%	+$3.05M	0.16%	50
2018 Q3	$1.85M	Buy	+30,000	New	+$1.93M	0.08%	63

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Altrinsic Global Advisors's AERI Position: Q1 2022 in Review

Altrinsic Global Advisors sold out of Aerie Pharmaceuticals (AERI) in Q1 2022, closing a stake of 270,000 shares — an estimated $1.9M sold.

Altrinsic Global Advisors first reported a position in AERI in Q3 2018 and held it in 14 quarters. The position peaked at $4.51M in Q1 2019. 136 funds tracked by Wall St. Rank hold AERI as of Q1 2022.

Altrinsic Global Advisors reported no remaining Aerie Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Altrinsic Global Advisors sold 270,000 Aerie Pharmaceuticals shares in Q1 2022, an estimated $1.9M.
Altrinsic Global Advisors first reported a position in Aerie Pharmaceuticals in Q3 2018 and held it in 14 quarters.
Altrinsic Global Advisors's Aerie Pharmaceuticals position peaked at $4.51M in Q1 2019.
136 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2022.

Based on Altrinsic Global Advisors's 13F filing for Q1 2022, filed 16 May 2022.